THERAPEUTIC TRIAL OF MILACEMIDE IN PATIENTS WITH MYOCLONUS AND OTHER INTRACTABLE MOVEMENT-DISORDERS

We performed a therapeutic trial with the glycine precursor, milacemid e, on 10 patients with intractable movement disorders. Six had myoclon us of various etiologies and one each had progressive supranuclear pal sy, Filipino X-linked dystonia with parkinsonism, painful legs and mov ing toes, and stiff-person syndrome. Milacemide was initiated at a dos e of 2,400 mg/day, orally, and increased gradually to a maximum of 4,8 00 mg/day. No clear-cut observable improvement occurred. There were no serious adverse effects.